Mer­ck, Vi­a­tris agree to set­tle patent feud sur­round­ing di­a­betes drugs

The dis­pute be­tween Mer­ck and Vi­a­tris over the patent rights for block­buster di­a­betes drugs Janu­via and Janu­met is over — so long as a judge signs off.

At­tor­neys for both Mer­ck and My­lan Phar­ma­ceu­ti­cals — now a part of Vi­a­tris — re­quest­ed last week that the dis­trict court in West Vir­ginia en­ter a fi­nal judg­ment in the case (1:19-cv-00101-IMK) up­on re­mand from the Unit­ed States Court of Ap­peals for the Fed­er­al Cir­cuit, a court that has spe­cial ap­pel­late ju­ris­dic­tion over cer­tain types of cas­es. These cas­es in­clude patents, trade­marks and gov­ern­ment con­tracts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.